This treatment inhibited the transfer of exosomal PD-L1 from GC cells to bone marrow cells, thereby mitigating exosomal PD-L1-induced differentiation and expansion of myeloid-derived suppressor cells (MDSCs) within the tumor microenvironment [93]. The gene discussed is CD274; the disease is neoplasm.